Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT108 in advanced solid tumors
NCT07317505Phase 1Recruiting
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Start
- Dec 2025
- Primary completion
- Jul 2029
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of JMT108 in cancer (8 arms), sponsored by Conjupro Biotherapeutics, Inc. Primary endpoints: Dose Limiting Toxicities at 1 year and Tumor Response at 1 year. Started Dec 2025; status: recruiting.
02
Drugs
JMT108
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07317505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317505.